HA-Irinotecan: Phase III data

The double-blind, Australian Phase III ACO002 trial in 415 irinotecan-naive patients who failed previous therapy showed that HA-Irinotecan as part of FOLFIRI therapy as second- or third-line treatment missed the primary endpoint of improving median PFS vs. FOLFIRI therapy with standard irinotecan (5.5 months for both arms). A planned interim analysis of OS showed that both treatment arms led to an OS of about 14 months. Alchemia plans to further analyze the data and said it will report further on its review and corporate strategy in early 2015. ...